Clin Osteol 2024; 29(4): 143-146

The fragile beauty of bone -⁠ a perspective on fracture risk assessment in clinical practice: a case reportCase reports

Killinger Zdenko
V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava

In Blahoš's lecture, the author points out several aspects of bone quality and the possibilities of their use, not only when determining the risk of fracture, but also when deciding on the need for anti-porotic therapy. Briefly documents the development of diagnostic methods and therapeutic approaches in the last 30 years of Slovak osteology. Author focused on the role of bone densitometry in the diagnostic and therapeutic algorithm and progress in the position of DXA in real practice in the Slovak Republic in the given period. In conclusion, the author on a specific case report pointed out how individual bone quality parameters can influence the decision on the need for anti-porotic treatment.

Keywords: bone densitometry; bone quality; fracture risk

Published: December 11, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Killinger Z. The fragile beauty of bone -⁠ a perspective on fracture risk assessment in clinical practice: a case report. Clinical Osteology. 2024;29(4):143-146.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Payer J, Killinger Z et al. Osteoporóza. Herba: Bratislava 2012. ISBN 978-80-89171-94-1.
    2. Lewiecki EM, Laster AJ. Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 2006; 91(11): 4215-4222. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2006-1178>. Go to original source...
    3. Faulkner KG, Cummings SR, Black D et al. Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. J Bone Miner Res 1993; 8 : 1211-1217. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.5650081008>. Go to original source...
    4. Hans D, Goertzen AL, Krieg M-A et al. Bone Micro-Architecture Assessed by TBS Predicts Osteoporotic Fractures Independent of Bone Density: The Manitoba Study. J Bone Miner Res 2011; 26 : 2762-2769. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.499>. Go to original source...
    5. Krueger D, Fidler E, Libber J et al. Spine trabecular bone score subsequent to bone mineral density improves fracture discrimination in women. J Clin Densitom 2014; 17(1): 60-65. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2013.05.001>. Go to original source...
    6. Watts NB. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice. J Womens Health (Larchmt) 2011; 20(4): 525-531. Dostupné z DOI: <http://dx.doi.org/10.1089/jwh.2010.2294>. Go to original source...
    7. Kanis JA, McCloskey EV, Harvey NC et al. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int 2023; 34(1): 1-9. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-022-06567-9>. Go to original source...
    8. Pikner R, Palička V, Rosa J et al. Markery kostního obratu u osteoporózy: společné stanovisko k jejich využití Společnosti pro metabolická onemocnění skeletu České lékařské společnosti J. E. Purkyně (SMOS ČLS JEP) a České společnosti klinické biochemie České lékařské společnosti J. E. Purkyně (ČSKB ČLS JEP). Clin Osteol 2020; 25(2): 65-82.
    9. Colloca L, Miller F. The Nocebo Effect and Its Relevance for Clinical Practice. Psychosom Med 2011; 73(7): 598-603. Dostupné z DOI: <http://dx.doi.org/10.1097/PSY.0b013e3182294a50>. Go to original source...
    10. Payer J, Killinger Z, Ivana Sulková et al. Therapeutic adherence to bisphosphonates. Biomed Pharmacother 2007; 61(4): 191-193. Dostupné z DOI: <http://dx.doi.org/10.1016/j.biopha.2007.02.003>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.